September 18, 2024
Azome Therapeutics, an early-stage drug development company, presented data supporting its Receptor for Hyaluronan-Mediated Motility (RHAMM) antagonist technology at the 6th Annual Inflammasome Therapeutics Summit held September 10-12 in Boston, MA.
In a series of pre-conference workshops, Azome’s CEO, Elliott Gruskin, PhD and Head of the Scientific Advisory Board, Rashmin C. Savani, MBChB, were among a number of expert speakers exploring the latest in the biology of inflammasomes and indications for therapeutic targeting. Drs. Gruskin and Savani also led panel discussions on the clinical and regulatory considerations for inflammasome therapeutics across different diseases, including patient selection, targeted biomarkers, and specific short- and long-term outcome measures.
During the summit, Dr. Savani also presented a poster on the development of the company’s lead drug candidate, RHAMM antagonist AZM-152, as a potential preventive therapy for bronchopulmonary dysplasia (BPD). BPD, a chronic lung disease, is common among preterm infants, where respiratory failure is treated with ventilator and oxygen therapy.
The company’s novel RHAMM antagonist technology platform and its lead drug candidate, AZM-152, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several with significant unmet needs.
About Azome Therapeutics
Azome Therapeutics is focused on developing selective RHAMM antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.